Zum Inhalt

HealthOSArzneimittel

Arbeitsbereiche

Nachschlagen

Wirkstoffe & Arzneimittelsicherheit

Exakte Wirkstoffkennungen und zitierbare Passagen zu Wechselwirkungen, Gegenanzeigen und Nebenwirkungen.

Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.

RxNorm 05-Oct-2026 · geprüft 2026-10-26 · 1181 Präparate · 62955 Quellenpassagen · 167 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.

Quellenpassagen (1)

Nebenwirkungen · Jakavi

Jakavi 5 mg tablets Jakavi 10 mg tablets Jakavi 15 mg tablets Jakavi 20 mg tablets · Abschnitt 4.8 · PDF-Seite 17

HOS-126155 · Präparat HOS-096217

Acute GvHD Chronic Chronic GvHD Acute GvHD (Paediatric GvHD (Paediatric (REACH2) pool) (REACH3) pool) Frequency Frequency Frequency Frequency Adverse drug reaction category category category category Infections and infestations CMV infections Very common Very common Common Common CTCAE3 grade ≥3 Very common Common Common N/A5 Sepsis Very common Common -6 -6 CTCAE grade ≥34 Very common Common -6 -6 Urinary tract infections Very common Common Common Common CTCAE grade ≥3 Common Common Common Common BK virus infections -6 -6 Common Common CTCAE grade ≥3 -6 -6 Uncommon N/A5 Blood and lymphatic system disorders Thrombocytopenia1 Very common Very common Very common Very common CTCAE grade 3 Very common Very common Common Common CTCAE grade 4 Very common Very common Very common Very common 1 Anaemia Very common Very common Very common Very common CTCAE grade 3 Very common Very common Very common Very common Neutropenia1 Very common Very common Very common Very common CTCAE grade 3 Very common Very common Common Very common CTCAE grade 4 Very common Very common Common Very common Pancytopenia1,2 Very common Very common -6 -6 Metabolism and nutrition disorders Hypercholesterolaemia1 Very common Very common Very common Very common CTCAE grade 3 Common N/A5 Common Common CTCAE grade 4 Common N/A5 Uncommon Common Weight gain -6 -6 Common Common CTCAE grade ≥3 -6 -6 N/A5 Common Nervous system disorders Headache Common Common Very common Very common CTCAE grade ≥3 Uncommon N/A5 Common Common Vascular disorders Hypertension Very common Very common Very common Very common CTCAE grade ≥3 Common Very common Common Common Gastrointestinal disorders Increased lipase1 -6 -6 Very common Very common CTCAE grade 3 -6 -6 Common Common CTCAE grade 4 -6 -6 Uncommon Common 1 Increased amylase -6 -6 Very common Very common CTCAE grade 3 -6 -6 Common Common CTCAE grade 4 -6 -6 Common N/A5 Nausea Very common Common -6 -6 CTCAE grade ≥3 Uncommon N/A5 -6 -6 Constipation -6 -6 Common Common CTCAE grade ≥3 -6 -6 N/A5 N/A5

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

Vollständigen Kontext in der EMA-Fachinformation lesen →
Quellennachweis

Version 2025-11-10T13:51:00Z · SHA-256 f5e9d15f087df0766ff15826906abe609cecf3c8ef177236024d00e93ae36c17 · Passage 442bd0690febd266dd7923f00386fc53e346b9a45f3b1efff79cd20181f006af · Zeichen 14983–18853 im Abschnitt

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.